Acumen Pharmaceuticals Stock Beneish M Score

ABOS Stock  USD 2.27  0.01  0.44%   
This module uses fundamental data of Acumen Pharmaceuticals to approximate the value of its Beneish M Score. Acumen Pharmaceuticals M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Acumen Pharmaceuticals Piotroski F Score and Acumen Pharmaceuticals Altman Z Score analysis.
For more information on how to buy Acumen Stock please use our How to Invest in Acumen Pharmaceuticals guide.
  
At this time, Acumen Pharmaceuticals' Debt Ratio is comparatively stable compared to the past year. At this time, Acumen Pharmaceuticals' Graham Net Net is comparatively stable compared to the past year. Price Book Value Ratio is likely to gain to 0.73 in 2024, whereas Operating Cash Flow Per Share is likely to drop (0.93) in 2024.
At this time, it appears that Acumen Pharmaceuticals is an unlikely manipulator. The earnings manipulation may begin if Acumen Pharmaceuticals' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Acumen Pharmaceuticals executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Acumen Pharmaceuticals' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-4.85
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

N/A

Focus
Asset Quality

1.51

Focus
Expense Coverage

N/A

Focus
Gross Margin Strengs

0.96

Focus
Accruals Factor

N/A

Focus
Depreciation Resistance

0.8

Focus
Net Sales Growth

N/A

Focus
Financial Leverage Condition

2.31

Focus

Acumen Pharmaceuticals Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Acumen Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Total Assets173.5 M310.1 M
Way Down
Slightly volatile
Total Current Assets149 M246.6 M
Way Down
Slightly volatile
Property Plant Equipment110.5 K189.8 K
Way Down
Slightly volatile
Depreciation And Amortization174.8 K184 K
Notably Down
Pretty Stable
Selling General Administrative19.8 M18.8 M
Sufficiently Up
Slightly volatile
Total Current Liabilities7.4 M13 M
Way Down
Slightly volatile
Non Current Liabilities Total17.6 M30.2 M
Way Down
Very volatile
Short Term Debt1.8 M1.7 M
Sufficiently Up
Slightly volatile
Long Term Debt21.9 M24.6 M
Fairly Down
Slightly volatile
Gross Profit Margin1.091.14
Sufficiently Down
Slightly volatile

Acumen Pharmaceuticals Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Acumen Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Acumen Pharmaceuticals in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Acumen Pharmaceuticals' degree of accounting gimmicks and manipulations.

About Acumen Pharmaceuticals Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

174,800

At this time, Acumen Pharmaceuticals' Depreciation And Amortization is comparatively stable compared to the past year.

Acumen Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Acumen Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Acumen Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social

About Acumen Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Acumen Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acumen Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acumen Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Acumen Stock Analysis

When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.